Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study
第一作者单位：[1]Huazhong Univ Sci & Technol, Canc Ctr, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Dai Y.,Hong Q..Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study[J].ANNALS OF ONCOLOGY.2023,34:S710-S710.doi:10.1016/j.annonc.2023.09.2853.
APA：
Dai, Y.&Hong, Q..(2023).Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study.ANNALS OF ONCOLOGY,34,
MLA：
Dai, Y.,et al."Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, multicenter clinical study".ANNALS OF ONCOLOGY 34.(2023):S710-S710
医学